A case of Crimean-Congo haemorrhagic fever imported in Greece: Contact tracing and management of exposed healthcare workers.
Crimean-Congo haemorrhagic fever
contact tracing
healthcare workers
infection control
ribavirin
Journal
Journal of infection prevention
ISSN: 1757-1774
Titre abrégé: J Infect Prev
Pays: England
ID NLM: 101469725
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
23
09
2018
accepted:
14
04
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
21
8
2019
Statut:
ppublish
Résumé
Nosocomial transmission is a major mode of infection of Crimean-Congo haemorrhagic fever (CCHF). In May 2018, a patient with CCHF was hospitalised in Greece. Our aim was to present the management of healthcare workers (HCWs) to the CCHF case. Contact tracing, risk assessment and follow-up of exposed HCWs were performed. Testing (RT-PCR and/or serology) was offered to contacts. Post-exposure prophylaxis (PEP) with ribavirin was considered for high-risk exposures. Ninety-one HCWs were exposed to the case. Sixty-six HCWs were grouped as high-risk exposures. Ribavirin PEP was offered to 29 HCWs; seven agreed to receive prophylaxis. Forty-one HCWs were tested for CCHF infection; none was found positive. Gaps in infection control occurred. CCHF should be considered in patients with compatible travel history and clinical and laboratory findings. Early clinical suspicion and laboratory confirmation are imperative for the implementation of appropriate infection control measures. Ribavirin should be considered for high-risk exposures. Infection control capacity for highly pathogenic agents should increase.
Sections du résumé
BACKGROUND
BACKGROUND
Nosocomial transmission is a major mode of infection of Crimean-Congo haemorrhagic fever (CCHF). In May 2018, a patient with CCHF was hospitalised in Greece.
OBJECTIVE
OBJECTIVE
Our aim was to present the management of healthcare workers (HCWs) to the CCHF case.
METHODS
METHODS
Contact tracing, risk assessment and follow-up of exposed HCWs were performed. Testing (RT-PCR and/or serology) was offered to contacts. Post-exposure prophylaxis (PEP) with ribavirin was considered for high-risk exposures.
RESULTS
RESULTS
Ninety-one HCWs were exposed to the case. Sixty-six HCWs were grouped as high-risk exposures. Ribavirin PEP was offered to 29 HCWs; seven agreed to receive prophylaxis. Forty-one HCWs were tested for CCHF infection; none was found positive. Gaps in infection control occurred.
DISCUSSION
CONCLUSIONS
CCHF should be considered in patients with compatible travel history and clinical and laboratory findings. Early clinical suspicion and laboratory confirmation are imperative for the implementation of appropriate infection control measures. Ribavirin should be considered for high-risk exposures. Infection control capacity for highly pathogenic agents should increase.
Identifiants
pubmed: 31428197
doi: 10.1177/1757177419852666
pii: 10.1177_1757177419852666
pmc: PMC6683607
doi:
Types de publication
Journal Article
Langues
eng
Pagination
171-178Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Emerg Infect Dis. 2007 Jul;13(7):1097-100
pubmed: 18214191
Emerg Infect Dis. 2009 Jun;15(6):983-5
pubmed: 19523314
Scand J Infect Dis. 2009;41(11-12):877-80
pubmed: 19922073
Euro Surveill. 2010 Mar 11;15(10):19504
pubmed: 20403306
BMC Med. 2011 Dec 08;9:131
pubmed: 22152109
J Hosp Infect. 2013 Mar;83(3):185-92
pubmed: 23333147
Euro Surveill. 2014 Jul 31;19(30):null
pubmed: 25108534
Emerg Infect Dis. 2015 Jan;21(1):23-31
pubmed: 25529825
Int J Infect Dis. 2015 Apr;33:120-2
pubmed: 25576827
Clin Microbiol Infect. 2016 Apr;22(4):387.e1-387.e4
pubmed: 26806137
J Hosp Infect. 2016 Jul;93(3):304-8
pubmed: 27174232
J Gen Virol. 2016 Nov;97(11):2799-2808
pubmed: 27667586
Int J Infect Dis. 2017 Feb;55:118-121
pubmed: 28069471
Emerg Infect Dis. 2017 Jun;23(6):1005-1008
pubmed: 28518037
N Engl J Med. 2017 Jul 13;377(2):154-161
pubmed: 28700843
PLoS One. 2017 Sep 8;12(9):e0182315
pubmed: 28886039
Euro Surveill. 2018 Aug;23(35):null
pubmed: 30180928
J Virol Methods. 1998 Feb;70(2):129-37
pubmed: 9562407